Antibiotic treatment as sole management of Helicobacter pylori-negative gastric MALT lymphoma: a single center experience with prolonged follow-up

Annals of Hematology

Volumn 94, Issue 6, 2015, Pages 969-973

  Raderer, Markus ^a   Wöhrer, Stefan ^a,d   Kiesewetter, Barbara ^a   Dolak, Werner ^a   Lagler, Heimo ^a   Wotherspoon, Andrew ^b   Muellauer, Leonhard ^a   Chott, Andreas ^c  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

^c V Department of Internal Medicine   (Austria)

^d Krankenhaus Wiener Neustadt   (Austria)

Author keywords

Antibiotics; Helicobacter pylori; MALT lymphoma

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; METRONIDAZOLE; PROTON PUMP INHIBITOR; ANTIINFECTIVE AGENT;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BREATH ANALYSIS; DISEASE COURSE; ERADICATION THERAPY; FEMALE; FOLLOW UP; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HISTOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MARGINAL ZONE LYMPHOMA; MIDDLE AGED; PRIORITY JOURNAL; SEROLOGY; STOMACH LYMPHOMA; SURVIVAL; TREATMENT OUTCOME; TREATMENT RESPONSE; DISEASE MANAGEMENT; LYMPHOMA, B-CELL, MARGINAL ZONE; LYMPHOMA, NON-HODGKIN; RETROSPECTIVE STUDY; STOMACH NEOPLASMS; TIME;

ADULT; AGED; ANTI-BACTERIAL AGENTS; DISEASE MANAGEMENT; FEMALE; FOLLOW-UP STUDIES; HELICOBACTER PYLORI; HUMANS; LYMPHOMA, B-CELL, MARGINAL ZONE; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84928640717     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-014-2298-3     Document Type: Article

References (24)

1. Swerdlow SH, Campo E, Harris NL et al (2008) The World Health Organization classification of tumours of haematopoietic and lymphoid tissues. WHO, Lyon
2. Ruskone-Fourmestraux A, Fischbach W, Aleman BMP et al (2011) EGILS consensus report. Gastric extranodal marginal zone B-cell lymphoma of MALT. Gut 60:747–758
3. Zucca E, Copie-Bergman C, Ricardi U et al (2013) Gastric marginal zone lymphoma of MALT-type: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 24(suppl 6):v144–v148
4. Zullo A, Hassan C, Cristofari F et al (2010) Effects of Helicobacter pylori eradication on early stage gastric mucosa-associated lymphoid tissue lymphoma. Clin Gastroenterol Hepatol 8:105–110
5. Steinbach G, Ford R, Glober G et al (1999) Antibiotic treatment of gastric lymphoma of mucosa-associated lymphoid tissue. An uncontrolled trial. Ann Intern Med 131:88–95
6. Ruskone-Fourmestraux A, Lavergne A, Aegerter PH et al (2001) Predictive factors for regression of gastric MALT lymphoma after anti-Helicobacter pylori treatment. Gut 48:297–303
7. Raderer M, Streubel B, Woehrer S et al (2006) Successful antibiotictreatment of Helicobacter pylori negative gastric mucosa associated lymphoid tissue lymphomas. Gut 55:616–618
8. Akamatsu T, Mochizuki T, Okiyama Y et al (2006) Comparison of localized gastric mucosa-associated lymphoid tissue (MALT) lymphoma with and without Helicobacter pylori infection. Helicobacter 11:86–95
9. Nozaki K, Nomura S, Shimizu N et al (2006) Helicobacter pylori negative/API2-MALT1 translocation-negative low-grade MALT lymphoma. Gastric Cancer 9:229–234
10. Dong G, Liu C, Ye H et al (2008) BCL10 nuclear expression and t(11;18)(q21;q21) indicate nonresponsiveness to Helicobacter pylori eradication of Chinese primary gastric MALT lymphoma. Int J Hematol 88:516–523
11. Terai S, Iijima K, Kato K et al (2008) Long-term outcomes of gastric mucosa-associated lymphoid tissue lymphomas after Helicobacter pylori eradication therapy. Tohoku J Exp Med 214:79–87
12. Nakamura T, Seto M, Tajika M et al (2008) Clinical features and prognosis of gastric MALT lymphoma with special reference to responsiveness to H. pylori eradication and API2-MALT1 status. Am J Gastroenterol 103:62–70
13. Sumida T, Kitadai Y, Hiyama T et al (2009) Antibodies to Helicobacter pylori and CagA protein are associated with the response to antibacterial therapy in patients with H. pylori positive API2-MALT1-negative gastric MALT lymphoma. Cancer Sci 100:1075–1081
14. Park HS, Kim YJ, Yang WI et al (2010) Treatment outcome of localized Helicobacter pylori-negative low-grade gastric MALT lymphoma. World J Gastroenterol 16:2158–2162
15. Nakamura S, Sugiyama T, Matsumoto T et al (2012) Long-term clinical outcome of gastric MALT lymphoma after eradication of Helicobacter pylori: a multicentre cohort follow-up study of 420 patients in Japan. Gut 61:507–513
16. Choi YJ, Kim N, Paik JH et al (2013) Characteristics of Helicobacter pylori-positive and Helicobacter-pylori negative gastric mucosa-associated lymphoid tissue lymphoma and their influence on clinical outcome. Helicobacter 18:197–205
17. Zullo A, Hassan C, Ridolda L et al (2013) Eradication therapy in Helicobacter pylori-negative, gastric low-grade mucosa-associated lymphoid tissue lymphoma patients. A systematic review. J CLin Gastroenterol 47:824–827
18. Copie-Bergman C, Wotherspoon AC, Capella C et al (2013) GELA histological scoring system for post-treatment biopsies of patients with gastric MALT lymphoma is feasible and reliable in routine practice. Br J Haematol 160(1):47–52
19. Akamatsu T, Mochizuki T, Okiyama Y, Matsumoto A, Miyabayashi H, Ota H (2006) Comparison of localized gastric mucosa-associated lymphoid tissue (MALT) lymphoma with and without Helicobacter pylori infection. Helicobacter 11:86–95
20. Chung SJ, Kim JS, Kim H, Kim SG, Kim CW, Jung HC, Song IS (2009) Long-term clinical outcome of Helicobacter pylori-negative gastric mucosa-associated lymphoid tissue lymphoma is comparable to that of H. pylori-positive lymphoma. J Clin Gastroenterol 43:3
21. Morgner A, Lehn N, Andersen LP, Thiede C, Bennedsen M, Trebesius K, Neubauer B, Neubauer A, Stolte M, Bayerdörffer E (2000) Helicobacter heilmannii-associated primary gastric low-grade MALT lymphoma: complete remission after curing the infection. Gastroenterology 118(5):821–828
22. Govi S, Dognini GP, Licata G et al (2010) Six-month oral clarithromycin regimen is safe and active in extranodal marginal zone B-cell lymphomas: final results of a single-centre phase II trial. Br J Haematol 150(2):226–229
23. Kiesewetter B, Raderer M (2013) Antibiotic therapy in nongastrointestinal MALT lymphoma: a review of the literature. Blood 122(8):1350–1357
24. Ye H, Liu H, Raderer M et al (2003) High incidence of t(11;18)(q21;q21) in Helicobacter pylori-negative gastric MALT lymphoma. Blood 101(7):2547–2580